» Articles » PMID: 31663611

Key Associations for Hepatitis C Virus Genotypes in the Middle East and North Africa

Overview
Journal J Med Virol
Specialty Microbiology
Date 2019 Oct 31
PMID 31663611
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to investigate the epidemiology of hepatitis C virus (HCV) genotypes in the Middle East and North Africa (MENA) through an analytical and quantitative meta-regression methodology. For the most common genotypes 1, 3, and 4, country/subregion explained more than 77% of the variation in the distribution of each genotype. Genotype 1 was common across MENA, and was more present in high-risk clinical populations than in the general population. Genotype 3 was much more present in Afghanistan, Iran, and Pakistan than the rest of countries, and was associated with transmission through injecting drug use. Genotype 4 was broadly disseminated in Egypt in all populations, with overall limited presence elsewhere. While genotype 2 was more present in high-risk clinical populations and people who inject drugs, most of the variation in its distribution remained unexplained. Genotypes 5, 6, and 7 had low or no presence in MENA, limiting the epidemiological inferences that could be drawn. To sum up, geography is the principal determinant of HCV genotype distribution. Genotype 1 is associated with transmission through high-risk clinical procedures, while genotype 3 is associated with injecting drug use. These findings demonstrate the power of such analytical approach, which if extended to other regions and globally, can yield relevant epidemiological inferences.

Citing Articles

Hepatitis C risk score as a tool to identify individuals with HCV infection: a demonstration and cross-sectional epidemiological study in Egypt.

El-Khoury R, Chemaitelly H, Alaama A, Hermez J, Nagelkerke N, Abu-Raddad L BMJ Open. 2024; 14(6):e085506.

PMID: 38950989 PMC: 11340217. DOI: 10.1136/bmjopen-2024-085506.


Simultaneous Hepatitis C Virus Genotyping and Variant Detection in Patients with Thalassemia: A Single-Center Phylogenetic Study.

Safarnezhad Tameshkel F, Karbalaie Niya M, Zamani F, Ajdarkosh H, Khoonsari M, Faraji A Middle East J Dig Dis. 2023; 14(1):124-130.

PMID: 36619727 PMC: 9489335. DOI: 10.34172/mejdd.2022.265.


Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt.

Shoun A, Abozahra R, Baraka K, Mehrez M, Abdelhamid S Microorganisms. 2022; 10(4).

PMID: 35456731 PMC: 9024585. DOI: 10.3390/microorganisms10040679.


Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia.

Alotaibi A, Shamas N, Ansari U, Sanai F, Alshahrani A, Fathelrahman A J Pharm Bioallied Sci. 2022; 13(3):317-324.

PMID: 35017888 PMC: 8698081. DOI: 10.4103/jpbs.jpbs_166_21.


Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt.

Ayoub H, Chemaitelly H, Kouyoumjian S, Abu-Raddad L Int J Epidemiol. 2020; 49(3):798-809.

PMID: 32357208 PMC: 7394952. DOI: 10.1093/ije/dyaa052.


References
1.
Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian S, Abu-Raddad L . Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2017; 90(1):131-141. PMC: 5724492. DOI: 10.1002/jmv.24921. View

2.
Chaabna K, Kouyoumjian S, Abu-Raddad L . Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One. 2016; 11(2):e0149966. PMC: 4764686. DOI: 10.1371/journal.pone.0149966. View

3.
Fadlalla F, Mohamoud Y, Mumtaz G, Abu-Raddad L . The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. PLoS One. 2015; 10(3):e0121873. PMC: 4372394. DOI: 10.1371/journal.pone.0121873. View

4.
Mohamoud Y, Miller F, Abu-Raddad L . Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker. World J Gastroenterol. 2014; 20(36):12734-52. PMC: 4177460. DOI: 10.3748/wjg.v20.i36.12734. View

5.
Mahmud S, Mumtaz G, Chemaitelly H, Al Kanaani Z, Kouyoumjian S, Hermez J . The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction. 2020; 115(7):1244-1262. PMC: 7318323. DOI: 10.1111/add.14944. View